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Abstract
IMPORTANCE Severely energy-restricted diets are themost effective dietary obesity treatment.
However, there are concerns regarding potential adverse effects on body composition.
OBJECTIVE To compare the long-term effects of weight loss via severe vs moderate energy
restriction on leanmass and other aspects of body composition.
DESIGN, SETTING, AND PARTICIPANTS The Type of EnergyManipulation for Promoting Optimum
Metabolic Health and Body Composition in Obesity (TEMPO) Diet Trial was a 12-month, single-
center, randomized clinical trial. A total of 101 postmenopausal women, aged 45 to 65 years with
bodymass index (calculated as weight in kilograms divided by height in meters squared) from 30 to
40,whowere at least 5 years aftermenopause, had fewer than 3 hours of structured physical activity
per week, and lived in the Sydneymetropolitan area of New SouthWales, Australia, were recruited
between March 2013 and July 2016. Data analysis was conducted between October 2018 and
August 2019.
INTERVENTION Participants were randomized to either 12 months of moderate (25%-35%) energy
restrictionwith a food-based diet (moderate intervention) or 4months of severe (65%-75%) energy
restriction with a total meal replacement diet followed by moderate energy restriction for an
additional 8 months (severe intervention). Both interventions had a prescribed protein intake of 1.0
g/kg of actual body weight per day, and physical activity was encouraged but not supervised.
MAINOUTCOMES ANDMEASURES The primary outcomewas whole-body leanmass at 12 months
after commencement of intervention. Secondary outcomes were body weight, thighmuscle area
andmuscle function (strength), bonemineral density, and fat mass and distribution, measured at 0,
4, 6, and 12 months.
RESULTS A total of 101 postmenopausal women were recruited (mean [SD] age, 58.0 [4.2] years;
mean [SD] weight, 90.8 [9.1] kg; mean [SD] body mass index, 34.4 [2.5]). Compared with the
moderate group at 12 months, the severe group lost more weight (effect size, −6.6 kg; 95% CI, −8.2
to −5.1 kg), lost more whole-body lean mass (effect size, −1.2 kg; 95% CI, −2.0 to −0.4 kg), and lost
more thigh muscle area (effect size, −4.2 cm2; 95% CI, −6.5 to −1.9 cm2). However, decreases in
whole-body leanmass and thighmuscle areawere proportional to total weight loss, and therewas no
difference inmuscle (handgrip) strength between groups. Total hip bonemineral density (effect size,
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Abstract (continued)
−0.017 g/cm2; 95% CI, −0.029 to −0.005 g/cm2), whole-body fat mass (effect size, −5.5 kg; 95% CI,
−7.1 to −3.9 kg), abdominal subcutaneous adipose tissue (effect size, −1890 cm3; 95% CI, −2560 to
−1219 cm3), and visceral adipose tissue (effect size, −1389 cm3; 95% CI, −1748 to −1030 cm3) loss
were also greater for the severe group than for themoderate group at 12 months.
CONCLUSIONS ANDRELEVANCE Severe energy restriction had no greater adverse effect on
relative whole-body leanmass or handgrip strength compared with moderate energy restriction and
was associated with 2-fold greater weight and fat loss over 12 months. However, there was
significantly greater loss of total hip bonemineral density with severe vsmoderate energy restriction.
Therefore, caution is necessary when implementing severe energy restriction in postmenopausal
women, particularly those with osteopenia or osteoporosis.
TRIAL REGISTRATION anzctr.org.au Identifier: 12612000651886
JAMA Network Open. 2019;2(10):e1913733. doi:10.1001/jamanetworkopen.2019.13733
Introduction
Effective obesity treatments are needed to reduce obesity-relatedmorbidities and costs.1,2 Themost
effective dietary obesity treatments are severely energy-restricted diets3,4 of less than 800 kcal/d
(<3350 kJ/d),5 which often involve replacing all or almost all foods with nutritionally replete meal
replacement products, such as shakes, soups, or bars (ie, total diet replacement). Severely energy-
restricted diets result in significantly greater short- and long-term3,4,6-8 weight loss compared with
food-based diets that involve moderately restricting dietary energy intake by approximately 500
kcal/d (2100 kJ/d). In addition, total meal replacement diets are cheaper than the average per capita
food expenditure in Australia and cost 3 times less to administer than food-based diets in terms of
dietetics support.9
Despite being an effective and affordable dietary obesity treatment, a number of prominent
clinical obesity treatment guidelines from around the world show limited support for the use of total
meal replacement diets,10,11 and these diets are not routinely used by health care professionals.9,12
This may be because of reported adverse effects (eg, hair loss, constipation, headaches, dizziness,
fatigue, and cholelithiasis),6 the lack of training and resources available for pretreatment evaluation
and monitoring during these diets, and possibly also concerns that severe energy restriction may
adversely affect body composition (ie, lean mass and bonemineral density [BMD]) compared with
moderate energy restriction. For example, some studies have reported that larger energy deficits
induce greater loss of fat-freemass in adults with overweight or obesity.13-16 In contrast, other studies
have shown no difference in lean bodymass following severe or moderate energy restriction in
participants with obesity.17,18 As another example, some studies in womenwith overweight or
obesity suggested that weight loss of more than 14% of initial weight during 3 to 4months resulted
in significant bone loss,19,20 whereas moderate weight loss of approximately 5% to 7% of initial body
weight over 6months resulted in little21 or no22 bone loss. In contrast, the Comprehensive
Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) trial showed that men and
womenwith overweight on a severely energy-restricted diet (albeit less restricted than the
previously described studies) showed no greater loss of whole-body or hip BMD than individuals on
a moderately energy-restricted diet.23 However, the studies cited here were not randomized clinical
trials, were pilot studies, were of limited duration (ie, 6 days to 6 months), or were not specifically
designed to assess muscle and bone health.
Although randomized clinical trials have evaluated the effects of severe vs moderate energy
restriction on long-termweight maintenance in adults with overweight and obesity,24,25 in our
review of the literature, no study directly compared the long-term effects of severe vs moderate
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energy restriction (to achieve fast vs slowweight loss, respectively) on leanmass and other aspects
of body composition in people with obesity. We aimed to address this in the Type of Energy
Manipulation for Promoting OptimumMetabolic Health and Body Composition in Obesity (TEMPO)
Diet Trial.
Methods
StudyDesign and Participants
The TEMPODiet Trial was a single-center, randomized clinical trial. Ethical approval was obtained
from the Sydney Local Health District, Royal Prince Alfred Hospital Human Research Ethics
Committee. It was conducted at the Charles Perkins Centre Royal Prince Alfred Clinic on the
University of Sydney campus in Camperdown, New SouthWales, Australia, with magnetic resonance
imaging (MRI) andmagnetic resonance spectroscopy (MRS) scans performed at I-Med Radiology
(Camperdown). Reporting in this article is aligned with the Consolidated Standards of Reporting
Trials (CONSORT) reporting guideline, and the full trial protocol can be found in Supplement 1.
Key inclusion criteria were postmenopausal women aged 45 to 65 years with bodymass index
(calculated asweight in kilograms divided by height inmeters squared) from 30 to 40, at least 5 years
after menopause, with less than 3 hours of structured physical activity per week (ie, sedentary), and
living in the Sydneymetropolitan area of New SouthWales, Australia. We included womenwith this
menopausal status for 2 reasons: first, to circumvent known effects of female hormone cycles and
the menopausal transition on parameters under investigation in the trial and, second, because
women older than 50 years have a 4-fold higher rate of osteoporosis and a 2-fold higher rate of
osteopenia thanmen.26 Participants with osteoporosis or diabetes and those taking medication
affecting body composition were excluded. The full inclusion and exclusion criteria and our rationale
for these have been detailed in our published protocol.27 The trial was conducted in accordancewith
the Declaration of Helsinki28 and Good Clinical Practice guidelines.29 All participants provided
written informed consent prior to participation.
Randomization
Participants were randomized (and enrolled) to either the severe or moderate intervention (Figure 1)
using stratified permuted block randomization.30 Specifically, they were stratified by age (ie, 45 to
<55 years and 55-65 years) and bodymass index (ie, 30 to <35 and 35-40). Individuals in each of the
4 stratified groups were then randomized in blocks of 2 and with a 1:1 ratio into 1 of 2
interventions.27,31 To avoid bias, randomization was undertaken by 1 of us (A.S.) who had no contact
with participants before randomization and was not involved in implementing the interventions.
None of us who undertook screening or clinical testing (R.V.S., S.M., C.H., A.A.G, and H.A.F.) were
aware of themethod used for randomization, and wewere not able to predict which intervention a
particular participant would be randomized to.
Procedures
Themoderate intervention involved amoderate energy restriction of 25% to 35% relative to
estimated energy expenditure for a total of 12 months (52 weeks). This was achieved using a food-
based diet, with recommendations based on the Australian Guide to Healthy Eating.32 The guide
provides recommendations on the average number of standard servings of the 5 core food groups
(ie, vegetables, fruits, grains and cereals, meat andmeat alternatives, and reduced fat dairy) that an
individual should consume tomeet nutritional requirements based on age and sex. To simplify
adherence to themoderate intervention, we defined 6 food groups. Themeat andmeat alternative
and reduced fat dairy food groups were collapsed into a proteins group, and starchy vegetables were
incorporated into the grains and cereals group to form a carbohydrates group, while participants also
had groups for vegetables, fruits, fats, and discretionary foods. The severe intervention involved a
severe energy restriction of 65% to 75% relative to estimated energy expenditure for 4 months (16
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weeks) or until a bodymass index of no lower than 20was reached, whichever came first. This was
achieved using a total meal replacement diet (KicStart meal replacement shakes and soups from
Prima Health Solutions) supplemented with a whey protein isolate (Beneprotein; Nestlé HealthCare
Nutrition) to achieve the prescribed protein target (described later). This was followed bymoderate
energy restriction (ie, the moderate intervention) for the remaining period to 12 months (52 weeks).
Both diets were individualized for each participant and were nutritionally sound. That is, the diet
used in themoderate intervention was designed tomeet nutrient requirements with minimum
energy intake,31 while the severe intervention used a commercial total meal replacement product
and supplemental protein that rendered it close to the recommended nutrient requirements.33 For
both interventions, a protein intake of 1.0 g/kg of actual body weight per day was prescribed.
Participants were encouraged to gradually increase step counts to a total of 8000 to 12 000 steps/d,
including 30 to 60min/d of moderate to vigorous physical activity.34 Although physical activity was
encouraged, it was not supervised. Since the use of food diaries to measure adherence to the
prescribed diet is difficult to assess because of missing dietary records and underreporting among
participants with overweight and obesity,35 weight loss was used to monitor adherence to the
diets.36 We expected approximately 1.5 to 2.5 kg/wk weight loss for participants in the severe
intervention6 and approximately 0.5 to 1.0 kg/wk weight loss for participants in themoderate
intervention.37 To increase adherence to the diet, participants attended individual dietary
appointments with the trial dietitian approximately every 2 weeks for the first 26 weeks of the
intervention (ie, at 1, 2, 4, 6, 8, 10, 12, 15, 16, 18, 20, 25, and 26weeks relative to commencement of
the dietary interventions, plus an extra appointment at 17 weeks for participants in the severe
intervention during their transition to themoderate intervention) and then approximately every
Figure 1. Trial FlowDiagram
2514 Individuals sent email enquiry
2514 Screened by email
401 Screened by telephone
151 Screened by face-to-face interview and medical review
2113 Did not proceed to telephone screening
250 Excluded
193 Did not meet eligibility criteria
57 Declined to participate 
50 Excluded
18 Did not meet eligibility criteria
32 Declined to participate 
101 Randomized
50 Randomized to the severe intervention 
46 Completed 12-month severe intervention 
4 Discontinued the trial 
2 Discontinued during 4-month
severe intervention
1 Felt unwell on testing day
1 Health reasons unrelated to trial
2 Discontinued after 4-month
severe intervention
1 Dissatisfied with diet
1 Lost to follow-up
51 Randomized to the moderate intervention 
39 Completed 12-month moderate intervention 
12 Discontinued the trial 
5 No longer able to commit
5 Dissatisfied with diet and/or weight loss
1 Lost to follow-up
1 No reason provided 
Themoderate intervention involved a food-based diet
with a 25% to 35% energy restriction for a total of 12
months (52 weeks). The severe intervention involved
total diet replacement with 65% to 75% energy
restriction for 4months (16 weeks) or until a body
mass index (calculated as weight in kilograms divided
by height in meters squared) of no lower than 20 was
reached, whichever came first, followed bymoderate
energy restriction until 12 months (52 weeks).
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month until 52 weeks (ie, at 29, 33, 37, 41, 45, 51, and 52 weeks). The development process and
rationale behind the dietary interventions for the TEMPODiet Trial as well as full details of the dietary
interventions have been published previously.31
Outcomes
This article reports the primary outcome for the TEMPODiet Trial (leanmass at 12 months after
commencement of the intervention) as well as the other outcomes related to body composition, all
of which are secondary outcomes. The body composition outcomes reported in this article are listed
in Table 1, and the full list of outcomes for this trial are published in our trial protocol.27 All body
Table 1. Baseline Characteristics for All Participants, Completers and Noncompleters, in the TEMPODiet Trial
Characteristic
Mean (SD)
Severe Group Moderate Group
All Participants
(n = 50)
Completers
(n = 46)
Noncompleters
(n = 4)
All Participants
(n = 51)
Completers
(n = 39)
Noncompleters
(n = 12)
Age, y 58.0 (4.4) 58.2 (4.3) 55.4 (5.0) 58.0 (4.2) 57.7 (4.2) 58.9 (4.3)
Height, m 1.62 (0.06) 1.62 (0.06) 1.64 (0.04) 1.63 (0.05) 1.63 (0.06) 1.63 (0.04)
Weight, kg 90.1 (9.4) 89.5 (9.4) 96.8 (7.4) 92.4 (8.3) 92.2 (8.6) 93.0 (7.4)
Body mass indexa 34.3 (2.5) 34.2 (2.4) 36.0 (2.5) 34.6 (2.5) 34.6 (2.7) 34.8 (2.1)
Lean Tissues
Whole-body lean mass, kgb 44.3 (4.9) 44.1 (5.0) 46.5 (3.6) 44.8 (4.0) 44.5 (4.1) 45.7 (3.7)
Thigh muscle area, cm2c 111.4 (15.1) 110.1 (14.6) 126.2 (14.0) 109.7 (13.4) 108.9 (13.4) 112.8 (13.5)
Muscle strength, kg
Dominant handd 29.80 (6.31) 29.27 (6.10) 35.75 (7.27) 30.00 (4.70) 29.97 (4.45) 30.08 (5.66)
Nondominant hand 27.90 (6.00) 27.39 (5.69) 33.75 (7.27) 27.90 (4.42) 28.03 (4.59) 27.80 (3.97)
Bone Mineral Density
Total hip, g/cm2e 0.988 (0.097) 0.980 (0.088) 1.079 (0.158) 0.972 (0.107) 0.973 (0.106) 0.967 (0.116)
Femoral neck, g/cm2e 0.810 (0.089) 0.803 (0.078) 0.882 (0.714) 0.815 (0.097) 0.821 (0.097) 0.793 (0.101)
Lumbar spine, g/cm2 1.001 (0.112) 0.994 (0.112) 1.080 (0.091) 1.019 (0.125) 1.004 (0.122) 1.066 (0.126)
Whole body, g/cm2b 1.093 (0.077) 0.089 (0.077) 1.139 (0.054) 1.100 (0.088) 1.089 (0.075) 1.133 (0.117)
Fat Mass and Distribution
Waist circumference, cm 108.3 (7.3) 108.4 (7.3) 107.8 (8.2) 108.8 (7.0) 109.1 (7.5) 107.6 (4.8)
Hip circumference, cm 118.6 (7.0) 117.9 (6.7) 126.9 (6.1) 121.3 (6.6) 121.3 (6.2) 121.3 (8.0)
Ratio of waist to hip circumferencef 0.915 (0.061) 0.921 (0.059) 0.850 (0.054) 0.898 (0.060) 0.901 (0.059) 0.891 (0.065)
Whole-body fat mass, kgb 42.2 (5.6) 41.8 (5.5) 46.7 (5.7) 43.5 (5.9) 43.5 (5.9) 43.4 (6.1)
Abdominal adipose tissue, cm3
Subcutaneous adipose tissuec,g 12 006 (3028) 11 833 (2981) 14 544 (3080) 12 176 (2508) 12 005 (2620) 12 811 (2030)
Visceral adipose tissuec 4544 (1702) 4604 (1705) 3884 (1756) 5123 (1954) 5074 (2002) 5296 (1854)
Intrahepatic lipid, %h 16.7 (16.9) 15.4 (15.3) 29.6 (27.8) 22.4 (19.1) 23.9 (20.8) 17.1 (11.2)
Thigh fat area, cm2
Subcutaneous fat areac 154.4 (28.9) 152.0 (26.4) 181.6 (45.0) 164.6 (43.4) 165.1 (36.0) 162.8 (65.6)
Subfascial fat areac 10.1 (4.1) 9.9 (4.0) 12.8 (4.2) 11.1 (4.3) 11.3 (4.6) 10.5 (2.9)
Intermuscular fat areac 6.07 (2.09) 6.00 (2.16) 6.92 (0.64) 6.78 (2.03) 6.82 (1.90) 6.63 (2.53)
Abbreviation: TEMPO, Type of Energy Manipulation for Promoting OptimumMetabolic
Health and Body Composition in Obesity.
a Calculated as weight in kilograms divided by height in meters squared.
b Data for 2 participants in themoderate group who completed the study are missing
because of machine failure.
c Data for 2 participants in the severe group who completed the study and 1 in the
moderate group who did not complete the study are missing because they did not
undergomagnetic resonance imaging scan or magnetic resonance spectroscopy.
d Data for 1 participant in the severe groupwho completed the study aremissing because
the participant underwent thumb tendon surgery, and data for 1 participant in the
moderate group who completed the study are missing because the participant had
scaphoid fracture.
e Data for 1 participant in themoderate group who completed the study are missing
because the scan could not be analyzed.
f Calculated as waist circumference divided by hip circumference.
g Data for 1 participant in the severe group who did not complete the study and 3
participants in themoderate group (2 completers, 1 noncompleter) are missing
because the scan was outside the window of analysis.
h Data for 7 participants in the severe groupwho completed the study and 11 participants
in themoderate group (8 completers; 3 noncompleters) aremissing because the scans
were invalid and unable to be accurately analyzed.
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composition outcomes were measured before the start of the intervention (0months) and at 4, 6,
and 12 months (with weight and waist and hip circumference additionally measured at 0.25 and 1
month) after commencing the interventions. Height was measured only at 0months. All data were
collected with participants lightly clothed (ie, in a close-fitting sports bra and leggings or, for MRI and
MRS scans, in a gown and underpants only), without shoes, and with all metal jewelry, accessories,
and electronic devices removed.
Dual-energy x-ray absorptiometry (DXA), using a DiscoveryW bone densitometer (Hologic),
was used to assess whole-body leanmass, whole-body fat mass, and BMD of the total left hip and
anterior posterior lumbar spine (L1-L4).38 A hydraulic hand dynamometer (Jamar, Model 5030J1;
PattersonMedical) was used to assess handgrip strength of the dominant and nondominant hands.
For 2 participants who were ambidextrous, the right and left hand were designated the dominant
and nondominant hand, respectively. Waist and hip circumferences weremeasured to the nearest 0.1
cm using a narrow, flexible, and inelastic steel tape (LufkinW606PM; Apex Tool Group). Waist
circumference wasmeasured at themidaxillary line (ie, at the halfway point between the bony
landmarks of the lowest rib and the top of the iliac crest), while the hip circumferencemeasurement
was taken at the point of greatest protuberance of the participant’s buttockswhen viewed from the
side. The ratio of waist to hip circumference was calculated by dividing waist circumference by hip
circumference. A 3-T MRI scanner (Discovery MR750; GE Healthcare) was used to assess abdominal
fat volume (subcutaneous and visceral adipose tissue from the diaphragm to the pelvis, with a slice
thickness of 10 mm and an interslice gap of 10 mm) as well as thigh muscle area and thigh fat area
(subcutaneous, subfascial, and intermuscular, with themedian slice between the base of the femoral
head andmidpatella selected for analysis unless therewere an even number of slices between these
points, in which case the inferior of the 2middle slices was selected). Intrahepatic lipid wasmeasured
by volume localized protonMRS (1H-MRS) and calculated as methylene peak area + methyl peak
area × 100 / water peak area, corrected for T2 effects. Accelerometers (SenseWear Pro Armband;
BodyMedia Inc) were used to assess physical activity.39 Physical activity data will not be presented in
this article; however, it was used as a covariate in our analysis. Physical activity data were only
included as a covariate in the analysis if participants wore the accelerometer for a minimum of 5 of 7
designated days for at least 85% of each 24-hour day. Mean physical activity across the days the
accelerometer was worn was then reported as metabolic equivalents of task (equal to total energy
expenditure divided by resting energy expenditure; calculated by SenseWear Professional Software
version 7.0 [BodyMedia Inc]).
Statistical Analysis
For our primary outcome of whole-body leanmass at 12 months after intervention commencement,
we calculated that a target sample size of 100 participants would provide a power of 90% at a
2-sided α level of 5%, allowing for up to 20% attrition as seen in previously published weight loss
interventions.40-42 Notably, attrition at 12 months in our trial was 16%, which fell within the attrition
prediction used in our sample size calculation.
Statistical analyses were performed using SPSS statistical software version 24 forWindows (IBM
Corp). Statistical significancewas accepted as P < .05, and tests were 2-tailed. Fisher exact tests were
used to compare categoric demographic characteristics (ie, race) and attrition between groups (ie,
severe vs moderate). To compare continuous variables between groups at baseline (0 months),
Mann-Whitney tests were used. All continuous variables were assessed for normality before analysis
using histograms and P-P plots. Where data were not normally distributed (ie, intrahepatic lipid and
subfascial thigh fat area), a natural log transformation was applied to obtain a normal distribution.
To compare longitudinal changes between groups, intention-to-treat analysis was performed
using data from all participants originally randomized, using random-effects linear mixed models.
Mixed-model analyses were used instead of standard repeatedmeasures analysis of variance
because of the likelihood that there would be dropouts andmissed visits that precluded the use of
the classic approach.43 Therefore, this model allowed for participants to have partial missing data
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and still be included without imputation. Intervention group and time (ie, 0, 4, 6, and 12 months for
all parameters, except waist circumference, hip circumference, and waist-to-hip ratio, which were
assessed at all of these points plus at 0.25 and 1 month) were included as fixed effects, and
participant was included as a random effect. For all outcomes, baseline values of the relevant variable
were added as a covariate in the analysis. As the degree of physical activity is known to influence
measures of body composition, physical activity (expressed in metabolic equivalents of task) was
added as a covariate, as measured at each point. When the overall P value for the interaction
between group and time was less than .05, comparisons between groups at each point were made,
using Bonferroni adjustments to correct for multiple comparisons. As a secondary analysis, the
model was further adjusted for weight at each point, because lighter individuals are known to have
lower whole-body lean mass and BMD than heavier individuals.44,45 This was to determine if there
was an effect of the interventions beyond that which would be expected due to weight loss.
Within-group changes were analyzed with repeatedmeasures linear-mixedmodels.
Intervention group and time were included in themodel as fixed effects and time as a repeated
measure, with physical activity (metabolic equivalents of task) added as a covariate. Maximum-
likelihood estimation was used, and an unstructured covariancematrix was specified. When the
overall P value for the interaction between group and time was less than .05, comparisons between
time points and baseline (0 months) within each group were made, using Bonferroni adjustments to
correct for multiple comparisons.
Results
Participants were recruited betweenMarch 2013 and July 2016, and 101 participants were
randomized to the trial (Figure 1). Participants had amean (SD) age of 58.0 (4.2) years, a mean (SD)
weight of 90.8 (9.1) kg, and amean (SD) bodymass index of 34.4 (2.5). At baseline (0months), there
were no differences between groups in age, race (severe: 47 of 50 [94.0%] white participants;
moderate: 48 of 51 [94.1%] white participants), or outcome variables (Table 1). Overall, 85 of 101
(84.2%) completed the 12-month intervention (46 of 50 [92.0%] in the severe group vs 39 of 51
[76.5%] in themoderate group). There were 3-fold fewer participants discontinuing the trial for the
severe group compared with themoderate group (4 vs 12 participants; P = .05) (Figure 1).
Weight
The severe group had a significantly lowerweight than themoderate group at all points after baseline
(effect size, −6.6 kg; 95% CI, −8.2 to −5.1 kg; estimatedmarginal mean at 12 months: −15.3 [95% CI,
−18.1 to −12.5] vs −8.4 [95% CI, −11.4 to −5.4] kg; P < .001) (Figure 2A and Table 2). Both groups had
significant decreases in weight at all points compared with baseline. At 12 months, 41 of 46
participants (89.1%) in the severe intervention who remained in the study had lost at least 10% of
their baseline weight compared with 14 of 39 participants (35.9%) in themoderate intervention who
remained in the study (P < .001) (Figure 2B). Assuming participants who dropped out of the study
did not achieve at least 10%weight loss, then 41 of 50 participants (82.0%) in the severe group lost
at least 10% of baseline weight compared with 14 of 51 participants (27.5%) in themoderate group
(P < .001). This represents a 2.5-fold to 3.0-fold greater likelihood of losing a clinically significant
amount of weight (ie, 10%) with the severe vs moderate intervention.
Lean Tissues
The severe group had significantly lower values of whole-body leanmass compared with the
moderate group at all points after baseline (effect size, −1.2 kg; 95% CI, −2.0 to −0.4 kg; estimated
marginal mean at 12 months: −3.2 [95% CI, −4.1 to −2.3] kg vs −2.1 [95% CI, −3.1 to −1.2] kg; P = .005)
(Figure 3A and Table 2). Similar findings were seen when the analysis was run for only participants
who completed the trial. After adjusting for body weight at each point, the severe group still had
significantly lower values of whole-body leanmass than themoderate group at 4months but not at
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6 or 12 months. Both groups had significant decreases in whole-body leanmass at all points
compared with baseline (estimatedmarginal mean at 12 months, severe group: −3.2 [95% CI, −4.1 to
−2.3] kg; moderate group: −2.1 [95% CI, −3.1 to −1.2] kg; P = .005).
Similar to whole-body leanmass, the severe group had significantly lower thighmuscle area
than themoderate group at all points after baseline (effect size, −4.2 cm2; 95% CI, −6.5 to −1.9 cm2;
estimatedmarginal mean at 12months: −8.2 [95%CI, −10.7 to −5.7] cm2 vs −3.9 [95%CI, −6.5 to −1.4]
cm2; P < .001) (Figure 3B and Table 2). After adjusting for body weight at each point, the severe
group still had significantly lower values of thighmuscle area compared with themoderate group at
4 months but not at 6 or 12 months. Both groups had significant decreases in thigh muscle area at all
points compared with baseline.
There were no significant differences between the severe andmoderate groups in dominant or
nondominant handgrip strength (estimatedmarginal mean at 12 months for the dominant hand:
−0.49 [95% CI, −2.32 to 1.35] kg vs −1.54 [95% CI, −3.46 to 0.38] kg; nondominant hand: −1.06 [95%
CI, −2.91 to 0.79] kg vs −1.83 [95% CI, −3.78 to −0.13] kg) (Table 2; eFigure, A in Supplement 2). The
severe group did not show any significant changes from baseline in either dominant or nondominant
handgrip strength. Themoderate group had a significant decrease from baseline to 4months in the
nondominant hand (estimated marginal mean, −1.61; 95% CI, −3.07 to −0.14; P = .02), but no
significant changes from baseline in the dominant hand (Table 2; eFigure, A in Supplement 2).
BoneMineral Density
The severe group had significantly lower total hip BMD than themoderate group at 12months (effect
size, −0.017 g/cm3; 95% CI, −0.029 to −0.005 g/cm2; estimatedmarginal mean: −0.032 [95% CI,
−0.045 to −0.029] g/cm2 vs −0.015 [95%CI, −0.028 to −0.002] g/cm2; P = .002), but there were no
significant differences between groups in lumbar spine BMD (estimatedmarginal mean: −0.033
[95% CI, −0.046 to −0.014] g/cm2 vs −0.021 [95% CI, −0.038 to −0.003] g/cm2; P = .27) or whole-
body BMD (estimatedmarginal mean: −0.008 [95% CI, −0.008 to 0.002] g/cm2 vs −0.010 [95% CI,
−0.021 to 0.000] g/cm2; P = .38) (Figure 3C and D and Table 2; eFigure, B in Supplement 2). After
adjusting our analyses for weight at each point, there was still a significantly lower total hip BMD in
the severe group compared with the moderate group at 12 months. Both groups had significant
decreases from baseline (Figure 3C and D and Table 2; eFigure, B in Supplement 2). Specifically, the
Figure 2.Weight Changes in PostmenopausalWomenWith Obesity During the Type of EnergyManipulation for Promoting OptimumMetabolic Health
and Body Composition in Obesity (TEMPO) Diet Trial
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Table 2. Changes FromBaseline for Body CompositionWith the Severe andModerate Energy Restriction Interventions of the TEMPODiet Trial
Measurement No.
Severe Group,
Estimated Marginal Mean
(95% CI) No.
Moderate Group,
Estimated Marginal Mean
(95% CI) P Valuea
Weight change, kg
0.25 mo 48 −2.7
(−3.0 to −2.4)b
51 −1.5
(−1.8 to 1.2)b
.02
1 mo 48 −6.3
(−6.8 to −5.8)b
48 −3.1
(−3.6 to −2.6)b
<.001
4 mo 48 −17.4
(−18.9 to −16.0)b
43 −7.1
(−8.6 to −5.6)b
<.001
6 mo 48 −17.8
(−19.7 to −15.9)b
43 −8.5
(−10.5 to −6.6)b
<.001
12 mo 46 −15.3
(−18.1 to −12.5)b
39 −8.4
(−11.4 to −5.4)b
<.001
Weight change, % of baseline
0.25 mo 48 −3.1
(−3.4 to −2.7)b
51 −1.6
(−1.9 to 1.2)b
.02
1 mo 48 −7.0
(−7.6 to −6.5)b
48 −3.4
(−4.0 to −2.8)b
<.001
4 mo 48 −19.6
(−21.3 to −17.9)b
43 −7.7
(−9.4 to −6.0)b
<.001
6 mo 48 −19.9
(−22.0 to −17.8)b
43 −9.3
(−11.4 to −7.1)b
<.001
12 mo 46 −17.3
(−20.3 to −14.3)b
39 −8.8
(−12.0 to −5.7)b
<.001
Body mass index changec
0.25 mo 48 −1.05
(−1.17 to −0.93)b
51 −0.55
(−0.67 to −0.43)b
.02
1 mo 48 −2.39
(−2.57 to −2.21)b
48 −1.17
(−1.35 to −0.99)b
<.001
4 mo 48 −6.61
(−7.15 to −6.07)b
43 −2.67
(−3.22 to −2.13)b
<.001
6 mo 48 −6.73
(−7.44 to −6.02)b
43 −3.19
(−3.92 to −2.46)b
<.001
12 mo 46 −5.81
(−6.89 to −4.74)b
39 −3.17
(−4.31 to −2.02)b
<.001
Lean tissue change
Whole-body lean mass, kgd
4 mo 48 −3.7
(−4.4 to −2.9)b
42 −1.4
(−2.1 to −0.7)b
<.001
6 mo 47 −3.0
(−4.0 to −2.1)b
40 −1.9
(−2.9 to −1.0)b
.002
12 mo 45 −3.2
(−4.1 to −2.3)b
37 −2.1
(−3.1 to −1.2)b
.005
Thigh muscle area, cm2
4 mo 46 −12.7
(−15.1 to −10.2)b
42 −3.3
(−5.5 to −1.0)b
<.001
6 mo 45 −8.7
(−11.1 to −6.4)b
40 −4.4
(−6.6 to −2.3)b
<.001
12 mo 43 −8.2
(−10.7 to −5.7)b
38 −3.9
(−6.5 to −1.4)b
<.001
Muscle strength change, kg
Dominant hand
4 mo 47 0.29
(−1.38 to 1.95)
43 −2.00
(−3.56 to −0.43)
NAe
6 mo 46 −0.36
(−2.02 to 1.33)
40 −1.05
(−2.63 to 0.53)
NAe
12 mo 42 −0.49
(−2.32 to 1.35)
39 −1.54
(−3.46 to 0.38)
NAe
Nondominant hand
4 mo 48 −0.59
(−2.15 to 0.97)
43 −1.61
(−3.07 to −0.14)f
NAe
6 mo 47 −0.42
(−2.14 to 1.31)
41 −1.16
(−2.81 to 0.49)
NAe
12 mo 43 −1.06
(−2.91 to 0.79)
38 −1.83
(−3.78 to −0.13)
NAe
(continued)
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Table 2. Changes FromBaseline for Body CompositionWith the Severe andModerate Energy Restriction Interventions of the TEMPODiet Trial (continued)
Measurement No.
Severe Group,
Estimated Marginal Mean
(95% CI) No.
Moderate Group,
Estimated Marginal Mean
(95% CI) P Valuea
Bone mineral density change, g/cm2d
Total hip
4 mo 48 −0.018
(−0.029 to −0.006)b
42 −0.008
(−0.018 to 0.003)
.10
6 mo 48 −0.020
(−0.031 to −0.008)b
42 −0.008
(−0.019 to −0.002)
.06
12 mo 46 −0.032
(−0.045 to −0.029)b
38 −0.015
(−0.028 to −0.002)f
.002
Femoral neck
4 mo 48 0.013
(−0.034 to 0.008)
42 −0.011
(−0.031 to 0.009)
.99
6 mo 48 −0.018
(−0.039 to 0.002)
42 −0.012
(−0.032 to 0.008)
.65
12 mo 46 −0.034
(−0.054 to −0.014)b
38 −0.020
(−0.040 to −0.001)
.23
Lumbar spine
4 mo 47 −0.004
(−0.019 to 0.011)
41 −0.007
(−0.021 to 0.007)
.54
6 mo 48 −0.021
(−0.036 to −0.005)g
42 −0.011
(−0.025 to 0.003)
.33
12 mo 46 −0.033
(−0.046 to −0.014)b
38 −0.021
(−0.038 to −0.003)f
.27
Whole body
4 mo 48 0.006
(−0.006 to 0.017)
42 −0.003
(−0.014 to 0.008)
.05
6 mo 47 0.004
(−0.007 to 0.015)
40 0.000
(−0.010 to 0.010)
.32
12 mo 45 −0.008
(−0.008 to 0.002)
37 −0.010
(−0.021 to 0.000)f
.38
Fat mass and distribution change
Waist circumference, cm
0.25 mo 48 −1.9
(−2.8 to −0.9)b
51 −0.3
(−1.2 to 0.7)
.04
1 mo 48 −4.6
(−5.7 to −3.5)b
48 −2.0
(−3.1 to −0.9)b
.004
4 mo 48 −15.2
(−17.1 to −13.2)b
43 −5.5
(−7.3 to −3.6)b
<.001
6 mo 48 −15.4
(−17.8 to −12.9)b
42 −6.1
(−8.6 to −3.6)b
<.001
12 mo 46 −14.3
(−17.3 to −11.3)b
38 −6.9
(−10.1 to −3.7)b
<.001
Hip circumference, cm
0.25 mo 48 −1.2
(−2.2 to −0.1)f
51 −0.5
(−1.5 to 0.6)
.04
1 mo 48 −3.6
(−4.5 to −2.6)b
48 −1.9
(−2.8 to −0.9)b
.001
4 mo 48 −12.2
(−13.8 to −10.7)b
43 −5.6
(−7.0 to −4.1)b
<.001
6 mo 48 −13.2
(−15.2 to −11.2)b
42 −6.6
(−8.5 to −4.6)b
<.001
12 mo 46 −10.3
(−12.7 to −7.8)b
38 −6.2
(−8.9 to −3.5)b
<.001
Ratio of waist to hip circumferenceh
0.25 mo 48 −0.002
(−0.040 to 0.036)
51 0.003
(−0.034 to 0.041)
.29
1 mo 48 −0.006
(−0.044 to 0.031)
48 0.004
(−0.034 to 0.041)
.30
4 mo 48 −0.027
(−0.065 to 0.012)
43 −0.003
(−0.040 to 0.004)
<.001
6 mo 48 −0.021
(−0.060 to 0.018)
42 0.004
(−0.035 to 0.043)
.001
12 mo 46 −0.038
(−0.075 to −0.001)f
38 −0.005
(−0.046 to 0.035)
<.001
(continued)
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Table 2. Changes FromBaseline for Body CompositionWith the Severe andModerate Energy Restriction Interventions of the TEMPODiet Trial (continued)
Measurement No.
Severe Group,
Estimated Marginal Mean
(95% CI) No.
Moderate Group,
Estimated Marginal Mean
(95% CI) P Valuea
Whole-body
fat mass change, kgd
4 mo 48 −11.4
(−12.6 to −10.1)b
42 −4.6
(−5.8 to −3.4)b
<.001
6 mo 47 −12.2
(−13.8 to −10.6)b
40 −5.5
(−7.1 to −3.9)b
<.001
12 mo 45 −10.2
(−12.1 to −8.4)b
37 −5.5
(−7.5 to −3.4)b
<.001
Abdominal adipose
tissue change, cm3
Subcutaneous
4 mo 46 −3627
(−4188 to −3065)b
41 −1387
(−1915 to −859)b
<.001
6 mo 45 −4254
(−4964 to −3545)b
40 −1814
(−2498 to −1129)b
<.001
12 mo 43 −3391
(−4220 to −2562)b
37 −1624
(−2511 to −736)b
<.001
Visceral
4 mo 46 −1948
(−2250 to −1646)b
42 −719
(−999 to −439)b
<.001
6 mo 45 −2386
(−2736 to −2035)b
40 −983
(−1312 to −654)b
<.001
12 mo 42 −2379
(−2839 to −1919)b
38 −1077
(−1561 to −594)b
<.001
Intrahepatic lipid changei
4 mo 45 0.25
(0.18 to 0.35)b
40 0.53
(0.38 to 0.73)b
<.001
6 mo 45 0.28
(0.19 to 0.40)b
39 0.49
(0.34 to 0.70)b
<.001
12 mo 41 0.32
(0.22 to 0.46)b
35 0.40
(0.27 to 0.61)b
.04
Thigh fat area change, cm2
Subcutaneous
4 mo 46 −41.4
(−47.4 to −35.3)b
42 −19.2
(−24.9 to −13.6)b
<.001
6 mo 45 −49.7
(−57.2 to −42.2)b
40 −26.5
(−33.8 to −19.3)b
<.001
12 mo 43 −38.9
(−48.6 to −29.2)b
38 −24.0
(−34.2 to −13.8)b
<.001
Subfasciali
4 mo 46 0.83
(0.77 to 0.89)b
42 0.95
(0.89 to 1.02)
<.001
6 mo 45 0.76
(0.71 to 0.83)b
40 0.92
(0.86 to 0.99)b
<.001
12 mo 43 0.79
(0.73 to 0.85)b
38 0.89
(0.82 to 0.96)b
<.001
Intermuscular
4 mo 46 −1.70
(−2.10 to −1.30)b
41 −0.91
(−1.32 to −0.49)b
<.001
6 mo 45 −2.09
(−2.54 to −1.63)b
40 −1.19
(−1.66 to −0.71)b
<.001
12 mo 43 −1.80
(−2.31 to −1.29)b
38 −1.05
(−1.58 to −0.51)b
.001
Abbreviations: NA, not applicable; TEMPO, Type of Energy Manipulation for Promoting
OptimumMetabolic Health and Body Composition in Obesity.
a P values for comparison between the severe andmoderate interventions at each point.
b P < .001 vs baseline for that group. For within-group comparisons between follow-up
and baseline values, a repeated-measures linear mixedmodel was used.
c Calculated as weight in kilograms divided by height in meters squared.
d Measured by dual-energy x-ray absorptiometry.
e Group by time interaction was not significant; therefore, a pairwise comparison was
not carried out.
f P < .05 vs baseline for that group. For within-group comparisons between follow-up
and baseline values, a repeated-measures linear mixedmodel was used.
g P < .01 vs baseline for that group. For within-group comparisons between follow-up
and baseline values, a repeated-measures linear mixedmodel was used.
h Calculated as waist circumference divided by hip circumference.
i Geometric mean ratio (95% CI).
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severe group had significant decreases from baseline in total hip BMD at all points and in lumbar
spine BMD at 6 and 12months, while themoderate group had significant decreases from baseline in
BMD in all 3 sites at 12 months.
There was a significant increase in the number of participants with osteopenia (defined as a
T-score of –1 to –2.5)46 at the femoral neck in the severe group but not themoderate group (severe:
0 months, 8 of 50 [16.0%]; 12 months, 18 of 46 [39.1%]; P = .04; moderate: 0 months, 12 of 50
[24.0%]; 12 months, 11 of 38 [28.9%]; P > .99). In contrast, in the total hip there was no difference
between the severe and moderate groups in the number of participants with osteopenia at 0 or 12
Figure 3. Effect of Severe vsModerate Energy Restriction on Body Composition in PostmenopausalWomen
With Obesity
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months (severe: 0months, 0 of 50; 12 months, 1 of 46 [2.2%]; moderate: 0months, 3 of 50 [6.0%];
12 months, 4 of 38 [10.5%]; P > .99). There were no participants with osteoporosis (defined as a
T-score of –2.5 or less)46 at 0 or 12 months in the severe or moderate groups.
FatMass andDistribution
Differences between the 2 groups in waist and hip circumference, or the ratio thereof, were observed
starting at 1 to 4months. Indeed, the severe group had significantly lower waist and hip
circumferences compared with themoderate group at all points after baseline (estimatedmarginal
mean of waist circumference at 12 months: −14.3 [95% CI, −17.3 to −11.3] cm vs −6.9 [95% CI, −10.1 to
−3.7] cm; P < .001; hip circumference at 12months: −10.3 [95%CI, −12.7 to −7.8] cm vs −6.2 [95%CI,
−8.9 to −3.5] cm; P < .001) (Figure 3E and Table 2), and the severe group had significantly lower
values of waist to hip ratio than themoderate group at 4, 6, and 12months, but not at 0.25 or 1month
(estimatedmarginal mean at 12 months: −0.038 [95% CI, −0.075 to −0.001] vs −0.005 [95% CI,
−0.046 to 0.035]; P < .001) (Table 2). Both groups had significant decreases in waist and hip
circumference at all points compared with baseline, except at 0.25months for themoderate group.
The severe group but not the moderate group had significant reductions in the ratio of waist to hip
circumference at 12 months compared with baseline. Moreover, compared with themoderate group,
the severe group had significantly lower whole-body fat mass (effect size, −5.5 kg; 95% CI, −7.1 to
−3.9 kg; estimatedmarginal mean at 12 months: −10.2 [95% CI, −12.1 to −8.4] kg vs −5.5 [95% CI, −7.5
to −3.4] kg; P < .001) (Figure 3F and Table 2), abdominal subcutaneous and visceral adipose tissue
volumes (subcutaneous adipose tissue: effect size, −1890 cm3; 95% CI, −2560 to −1219 cm3;
estimatedmarginal mean at 12months, −3391 [95%CI, −4220 to −2562] cm3 vs −1624 [95%CI, −2511
to −736] cm3; P < .001; visceral adipose tissue: effect size, −1389 cm3; 95% CI, −1748 to −1030 cm3;
estimatedmarginal mean at 12 months, −2379 [95% CI, −2839 to −1919] cm3 vs −1077 [95% CI, −1561
to −594] cm3; P < .001), intrahepatic lipid (geometric mean ratio at 12 months: 0.32 [95% CI, 0.22
to 0.46] vs 0.40 [95% CI, 0.27 to 0.61]; P = .04), thigh subcutaneous adipose tissue area (estimated
marginal mean at 12 months: −38.9 [95% CI, −48.6 to −29.2] cm2 vs −24.0 [95% CI, −34.2 to −13.8]
cm2; P < .001) as well as thigh subfascial fat area (geometric mean ratio at 12 months: 0.79 [95% CI,
0.73 to 0.85] vs 0.89 [95% CI, 0.82 to 0.96]; P < .001) and intermuscular fat area (estimated
marginal mean at 12months: −1.80 [95%CI, −2.31 to −1.29] cm2 vs −1.05 [95%CI, −1.58 to −0.51] cm2;
P < .001) at all points after baseline (Table 2; eFigure, C-H in Supplement 2). Both groups had
significant decreases from baseline in all these parameters.
Adverse Events
Therewere 8 adverse events (6 in the severe group, all related or possibly related to the intervention,
and 2 in themoderate group, neither related to the intervention). These adverse events were
reported by participants to the research team or occurred in the clinic during the clinical testing day.
No adverse event was considered serious. In the severe intervention, the adverse events were
hemorrhoids (2 participants [4.0%]), gallstones (2 participants [4.0%]), and hair loss (2 participants
[4.0%]). In the moderate intervention, there were 2 episodes of migraine (1 participant [2.0%]),
probably precipitated by fasting prior to clinical testing. This participant had a history of migraines
and continuedwith the trial but only underwent outcomemeasurements that did not require fasting.
Discussion
This randomized clinical trial demonstrated that, compared with moderate energy restriction over a
12-month period, severe energy restriction resulted in the following: (1) approximately 1.5 times as
much loss of whole-body lean mass and thigh muscle area, although these losses were proportional
to the amount of weight lost; (2) no difference in handgrip strength; (3) approximately twice asmuch
weight loss (with participants 2.5-3 times more likely to lose 10% of their initial weight); (4)
approximately twice as much total fat loss; and (5) a healthier fat distribution, as indicated by
JAMANetworkOpen | Nutrition, Obesity, and Exercise Effect of Severe vs Moderate Energy RestrictionWeight Loss on LeanMass and Body Composition
JAMA Network Open. 2019;2(10):e1913733. doi:10.1001/jamanetworkopen.2019.13733 (Reprinted) October 30, 2019 13/19
Downloaded From: https://jamanetwork.com/ by a University of Tasmania User  on 11/07/2019
approximately twice the loss of waist circumference, waist-to-hip circumference ratio, and
abdominal adipose tissue volume (subcutaneous and visceral). Participants in the severely energy-
restricted intervention were also 3 times less likely to discontinue the trial compared with those in
the moderately energy-restricted intervention. This is possibly because the large and rapid weight
loss associated with severe energy restriction has been shown to be encouraging and because the
total meal replacement diet used to achieve it is simple and convenient.47 These striking findings
were offset by an approximately 2.5-fold greater loss of total hip BMDwith severe energy restriction
compared with moderate energy restriction, a difference not accounted for by the greater
weight loss.
In this trial, the participants in themoderate group experienced approximately 1.3% reduction
in total hip BMD after 12 months, similar to the annual rate of BMD loss at the hip in the early
postmenopausal years (approximately 1.0%-1.4%).48 However, after the 12-month severe
intervention, total hip BMD loss (approximately 3.3%) was 2.4 to 3.3 times higher than these annual
BMD losses. Interestingly, the decrease in BMD continued over the whole 12 months of the severe
intervention, even though weight loss had plateaued by 6 months. This occurred despite a dietary
protein prescription of 1 g/kg of actual body weight per day in both groups31,49 and despite the fact
that the total meal replacement products used in this trial contained more than the Australian
recommended dietary intake for vitamin D and calcium for women aged 51 to 70 years.33 This loss of
BMDmay have been exacerbated because of the population selected for this trial (womenwith
obesity who were5 years postmenopausal). For example, in a study where men and womenwith
obesity were prescribed a total meal replacement diet until they reached 15% weight reduction in 3
to 6 months, all participant groups exhibited significant decreases in body weight at 2 years, and
both groups showed loss of BMD over 2 years, but this loss was statistically significant only among
women.50 This suggests that women may have a greater propensity to lose BMD following weight
loss. Research also suggests that BMD loss may be exacerbated in postmenopausal women (as in this
trial) compared with womenwho are still in the perimenopausal transition.48
The consequences of accelerated BMD loss with a severely energy-restricted dietary obesity
treatment are clinically concerning, especially if BMD loss continues beyond the 12-month
intervention, because it has been linked to an increased risk of osteoporosis and fragility fracture.51,52
However, this bone loss must be considered in light of the beneficial effects of substantial weight
loss on other health outcomes and health care costs. For example, although a 3% to 5% loss of initial
weight has generally been accepted as being clinically significant,11,53 recent research shows that
greater weight losses, ie, of 7.7%, 10%, 15%, or 20%, dose-dependently improve health
outcomes.54-57 In addition, if treated effectively, the costs of obesity-related health complications
would be significantly reduced.2 Thus, implementing effective obesity treatments is essential to
reducing obesity-related comorbidities and the associated costs. Thus, while the current trial should
not discourage the use of total meal replacement diets as a treatment for obesity in postmenopausal
women, further investigation is needed to determine the long-term consequences of the associated
BMD loss on health outcomes such as osteoporotic fractures and to determine howBMD losses could
be prevented in this population during and after these diets.
Strengths and Limitations
Strengths of this study include the 12-month randomized clinical trial design and the criterion-
standard techniques used for the assessment of body composition, notably our primary outcome of
lean mass. Another strength is that data variability was reduced by analysis of all data by a single
researcher (ie, S.M. for DXA, A.L.W.-T. for MRI, and S.E.K. for MRS). There are, however, some
limitations that must be noted, 1 of which is the technical limitation of DXA, which can only measure
2 tissue types at any time (eg, bone and soft tissue). Thus, being a 2-compartment model for the
determination of body composition, a possible confounder is that the DXA analysis assumes a
constant hydration of lean soft tissue, which is not always true, as hydration varies with age, sex, and
disease. To help control for this, all participants were measured after an overnight fast (8 hours)
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and after voiding their bladder once at home before attending our clinical research facility and again
when they arrived at the clinic. Another technical limitation of DXA is that changes in BMDobserved
with large weight losses might be exaggerated because of the varying amounts of soft tissue over
time, which can result in unpredictable errors in DXA bone measurements, to up to 20%.58 In
addition, DXA assesses bone quantity and not bone quality (eg, bonemicroarchitecture) or
osteoporotic fracture incidence, and it is possible that, despite BMD loss, bone quality and strength
may have been preserved in our participants. Despite these technical limitations, DXA remains the
criterion standard and the only available test formeasuring BMD in clinical practice aswell as being an
important predictor of osteoporotic fracture.59,60 A further limitation of our trial is that participants
were predominantly white, which limits the generalizability of the findings to populations of
other races.
Conclusions
In this randomized clinical trial, severe energy restriction with a total meal replacement diet in
postmenopausal womenwith obesity induced greater weight loss and approximately 1.5-fold as
much loss of whole-body leanmass and thighmuscle area compared with moderate energy
restriction over 12 months. While these losses of lean tissues were proportional to the amount of
weight lost and while muscle strength (ie, handgrip strength) was unaffected by severe vs moderate
energy restriction, there was an approximately 2.5-fold greater loss of total hip BMDwith severe
compared with moderate energy restriction, a difference not accounted for by the greater weight
loss. Therefore, caution is necessary when implementing severe energy restriction in
postmenopausal womenwith obesity, especially in those with osteopenia or osteoporosis, for whom
concurrent bone-strengthening treatments (eg,muscle strengthening exercises) are recommended.
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